

30 July 2018 Equity Research research@armsecurities.com.ng +234 1 270 1652

Price	₩ 2.04
FVE (last communicated)	N 3.38
52-week range	№ 1.00 – № 3.65
Market Cap. (N 'mn)	40,398
l-month Avg. Vol	5,222,960
Curr. PE	3.36x



FCMB Group Plc. (FCMB.NL)

Initial View

Strong Set of H1 Results

- First City Monument Bank Plc (FCMB) published its half-year results at the close of last week showing strong set of results across key line items. EPS of ₩0.29 was ~90% higher YoY on the back of moderation in funding cost, strong numbers on the non-interest revenue (NIR) line, and substantial decline in loan-loss provision. For context, despite decline in asset yields (-18bps YoY), moderation in funding cost (-44bps YoY) drove net interest margin (NIM) higher by 23bps YoY to 6.4%. In terms of NIR which increased by 28% YoY, the growth stemmed from Treasury Bills and FX trading income which grew by 126% and 406% YoY respectively. On loan-loss provision, reflecting recoveries worth ₩3.2 billion and 93% decline in collective provision, loan loss provision declined by 24% YoY. However, specific provision ran ahead at over double-fold YoY to ₩8.6 billion.
- Trading Income provides support to NIR. In Q2 18, FCMB reported trading income of ¥2.2 billion (+23% QoQ) on the back of 123% QoQ increase in income on treasury bills trading of ¥1.3 billion. However, FX and Bonds trading income declined 36% and 24% QoQ accordingly, to moderate the impact of strong income on treasury bills. Elsewhere, fee income expanded 7% QoQ supported by strong credit related fees and asset management fees. To our minds, we think the bank is certainly leveraging on synergy from its controlling stake in Legacy Pensions.

- **Funding cost takes a breather, but for how long?** Interest expense over the quarter declined by 5% QoQ, largely on the back of lower interest on banks (-62% QoQ) and customer deposits (-10% QoQ). Consequently, funding cost (WACF) printed at 5.9% (-23bps QoQ) to drive a 25bps QoQ expansion in NIM to 8.0%. Importantly, we noted a 243bps decrease in CASA share of total deposit to 67.6%, which does not align with the moderation in interest expense. Elsewhere, we are staggered at the sizable decline in interest on bank deposits in view of the 140% QoQ increase in deposit from banks. Thus, we will seek clarity from management to ascertain the sustainability of the benign funding cost in the face of an argumentative drive to grow deposit.
- Lower provisioning drives notable jump in earnings. Central to Q2 18 earnings is the sizable decline in loan-loss provision to N2.5 billion (-49% QoQ) reflecting 41% QoQ decline in specific provision to N3.2 billion, and N2.2 billion in recoveries. Consequently, annualized Cost of Risk printed at 1.7% (Q1 18: 3.3%). However, NPL tracked higher to 5.7% (Q1 18: 5.3%) largely due to the moderation in loan book (-1.7% QoQ). Elsewhere, reflecting higher AMCON charges, operating expenses increased by 11% QoQ to N19.7 billion, to drive higher cost-income ratio (CIR) of 75.7% (Q1 18: 68.6%).
- Net impact of lower provision, benign funding cost and higher NIR drove PBT of N3.8 billion (+18.2% QoQ) and EPS of N0.16 (21.4% QoQ, 118% YoY). Overall, ROE expanded to 3.1% (Q1 18: 2.7%, Q2 17: 2.6%). Capital adequacy ratio of 18% remains contentedly above supervisory limit of 15% and in line with our FY18 estimates.
- Our last communicated FVE on FCMB is N3.38 which translates to a **BUY** rating on the stock. We will revisit our numbers after further discussion with management.
- *H1 2018 analyst and investors conference call:* FCMB would be hosting a conference call tomorrow 31 July at 15.00 Lagos & London time. For more details, <u>click here</u>

Summary of Results and Forecast

¥'million	H2 2018	H2 2017	YoY (pps)	Q2 18	Q1 18	QoQ
Gross Earnings	83,925	77,508	8.3%	41,753	42,171	-1.0%
Net Interest Income	35,269	32,497	8.5%	17,518	17,751	-1.3%
Non-Interest Revenue	16,537	12,899	28.2%	8,479	8,058	5.2%
Operating Expenses	(37,369)	(31,708)	17.9%	(19,668)	(17,700)	11.1%
Impairment	(7,333)	(9,972)	-26.5%	(2,480)	(4,853)	-48.9%
РВТ	7,105	3,824	85.8%	3,848	3,256	18.2%
РАТ	5,726	3,019	89.7%	3,140	2,586	21.4%
EPS	0.29	0.15	89.7%	0.16	0.13	
N'million	Q2 2018	Q1 2018	QoQ			
Loans	585,982	595,823	-1.7%			
Total Assets	1,493,061	1,506,750	-0.9%			
Deposits	721,286	747,694	-3.5%			
Total Liabilities	1,051,570	1,082,382	-2.8%			
Net Assets	441,490	424,368	4.0%			
BVPS	22.29	21.43	4.0%			
	H2 2018	H2 2017	change (pps)	Q2 18	Q1 18	change (pps)
Assets Yields	11.7%	11.9%	(0.2)	12.0%	12.5%	(0.5)
WACF	6.0%	6.4%	(0.4)	5.9%	6.1%	(0.2)
Net Interest Margin	6.4%	6.2%	0.2	8.0%	7.7%	0.3
Cost-Income Ratio	72.1%	69.8%	2.3	75.7%	68.6%	7.1
Cost of Risk	2.5%	3.1%	(0.6)	1.7%	3.3%	(1.6)
ROE	2.6%	1.8%	0.8	3.1%	2.7%	0.4
CAR	18.0%	17.0%	1.0			

Source: Company Financials, ARM Research

ARM ratings and recommendations

ARM now employs a two-tier rating system which is based on systemic importance of the security under review and the deviation of our target price for the stock from current market price. We characterize systemic importance as a function of a stock's ranking among the group of top 20 stocks by NSE market capitalization over a trailing 6-month period (minimum) to the review date. We adopt a 5-point rating system for this category of stocks and a 3-point rating system for stocks outside this group. The choice of top 20 stocks arises from the consideration that this group of stocks constitutes >75% of overall market capitalization and stocks outside this group are generally less liquid and individually account for <<1% of market capitalization. For stocks in both categories, the basis for ratings subject to target price deviation is outlined below:

TOP 20		NON-TOP 20	
Rating	Deviation	Rating	Deviation
STRONG BUY	>20%	BUY	>20%
OVERWEIGHT	10% 20 %	NEUTRAL	5% - 20 %
NEUTRAL	0% 10 %	SELL	<5%
UNDERWEIGHT	-5% - 0%		
SELL	<-5%		

RECOMMENDATION H	XEY
Rating	Recommendation
BUY	Accumulate security to a substantial extent constrained only by portfolio diversification considerations
OVERWEIGHT	Accumulate security to an extent moderated by cognizance of its benchmark weight
NEUTRAL	Maintain status quo for security with respect to current holding—i.e. keep if already holding and don't buy otherwise—subject to reasonable portfolio constraints
UNDERWEIGHT	Minimize exposure to security taking cognizance of its index weighting
SELL	Sell-off security completely from portfolio
RESTRICTED	In certain circumstances, Asset & Resource Management ("ARM") Group policy and/or applicable law and regulations preclude certain types of communications, including an investment recommendation, during the course of ARM Securities' and/or ARM Group's engagement in an investment banking transaction and in certain other circumstances.

Copyright © 2018 ARM Securities Limited ("ARMS").

All rights reserved. Unauthorized use, reproduction, distribution, or disclosure of this document is strictly prohibited.

This material has been issued by ARM Securities Limited, a member of the Asset and Resource Management ("ARM") Group, and a Company regulated by the Nigerian Securities & Exchange Commission. The analyst(s) primarily responsible for preparing this research report, in whole or in part, certifies that with respect to each security or issuer covered; all the views expressed accurately reflect his/her personal views about the subject securities and issuers and no part of his/her compensation was, is, or will be, directly or indirectly, related to the inclusion of specific recommendations or views in the report.

This research report is based on information from sources that ARMS and its analysts believe to be reliable. Neither ARMS nor any of its research analysts, nor any member of the ARM Group, gives any representation or warranty, express or implied, or undertaking of any kind or assumes responsibility or liability of any kind with respect to the accuracy or completeness of the information set out in this report or any third party's use (or the results of such use) of such information. This report is provided solely for informational purposes and is not to be construed as providing advice, recommendations, or endorsements of any kind whatsoever. The investments and strategies discussed here may not be suitable for all investors; counsel of investment advisor should be obtained with regard to such investments and or strategies. This research report is not a replacement for advice from an accountant, lawyer, personal finance advisor or other category of investment advisor. The investments discussed in this report may oscillate in price or value. Opinions and information provided are made as of the date of the report issue and are subject to change without notice. This research report is not intended as an offer or solicitation for the purchase or sale of any financial instrument. Reference herein to any specific security or financial instrument does not necessarily constitute or imply its endorsement or recommendation by ARMS, its directors, officers, employees, or designated agents. Members of ARM may act as broker, advisor, or lender, or make a market in any investments or issuers referenced in this report. Further information on any of the securities discussed herein may be obtained upon request to ARMS. By accepting this document, you agree to be bound by the foregoing limitations.